Emily Pimblett - Eliem Therapeutics Principal Officer
| ELYMDelisted Stock | USD 5.02 0.16 3.29% |
Executive
Emily Pimblett is Principal Officer of Eliem Therapeutics
| Age | 40 |
| Phone | 877 354 3689 |
| Web | https://eliemtx.com |
Emily Pimblett Latest Insider Activity
Tracking and analyzing the buying and selling activities of Emily Pimblett against Eliem Therapeutics stock is an integral part of due diligence when investing in Eliem Therapeutics. Emily Pimblett insider activity provides valuable insight into whether Eliem Therapeutics is net buyers or sellers over its current business cycle. Note, Eliem Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eliem Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Emily Pimblett over three weeks ago Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to Rule 16b-3 | ||
Emily Pimblett over three months ago Disposition of 1245 shares by Emily Pimblett of Eliem Therapeutics at 7.2145 subject to Rule 16b-3 | ||
Emily Pimblett over three months ago Acquisition by Emily Pimblett of 5000 shares of Eliem Therapeutics subject to Rule 16b-3 | ||
Emily Pimblett over six months ago Acquisition by Emily Pimblett of 40000 shares of Eliem Therapeutics subject to Rule 16b-3 |
Eliem Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2454) % which means that it has lost $0.2454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3835) %, meaning that it created substantial loss on money invested by shareholders. Eliem Therapeutics' management efficiency ratios could be used to measure how well Eliem Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Afsaneh Mohebbi | PepGen | N/A | |
| Marianna Zipeto | Champions Oncology | N/A | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Anne DVM | Molecular Partners AG | N/A | |
| Mary JD | PepGen | 56 | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Jaya Goyal | PepGen | 56 | |
| Stefan Abele | Pharvaris BV | 54 | |
| Stephen JD | Shattuck Labs | 49 | |
| Chad Cowan | Century Therapeutics | N/A | |
| Xiaohong She | Adagene | 57 | |
| Ami Knoefler | Adagene | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Karin Heidemann | Champions Oncology | N/A | |
| Morgan Conn | Century Therapeutics | 55 | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Conor CPA | Shattuck Labs | N/A | |
| Ling Zhou | Adagene | N/A | |
| Arthur Hanson | Champions Oncology | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 |
Eliem Therapeutics Leadership Team
Elected by the shareholders, the Eliem Therapeutics' board of directors comprises two types of representatives: Eliem Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eliem. The board's role is to monitor Eliem Therapeutics' management team and ensure that shareholders' interests are well served. Eliem Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eliem Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO VP | ||
| MD MBA, Chief Officer | ||
| James JD, Gen VP | ||
| Jo PalmerPhillips, Chief Officer | ||
| Andrew MD, Principal Chairman | ||
| Valerie Morisset, Chief Development | ||
| Emily Pimblett, Principal Officer | ||
| BAO BCh, President CEO | ||
| Susan MS, VP Affairs | ||
| Robert MBA, CEO Pres | ||
| MBA MD, Interim Officer | ||
| Nishi MD, Senior Development |
Eliem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eliem Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 122.66 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 1.56 X | |||
| EBITDA | (40.27 M) | |||
| Net Income | (35.12 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |